Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06725953 · ClinicalTrials.gov registry record · NA
Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes
A NA study of Cancer Survivorship and Chemotherapy Side Effects, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06725953: Recruiting NA study of Cancer Survivorship and Chemotherapy Side Effects, sponsored by University of Oklahoma.
NCT06725953 is a NA study of Cancer Survivorship and Chemotherapy Side Effects that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 38 participants, below the 257-participant average among 11 other Cancer Survivorship trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06725953, a NA study of Cancer Survivorship and Chemotherapy Side Effects, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select pathophysiological processes. Research on chemotherapy-induced cognitive impairment (hereafter, 'chemo-brain') is therefore critical. Chemotherapy disrupts immune system function and antioxidant regulation, causing inflammatory molecule release and damaging the brain's blood vessels. The brain's vascular function and, possibly, its neurons, are subsequently impaired-likely contributing to chemo-brain. Type 2 diabetes (T2D), a common cancer survivor comorbidity, shares underlying pathophysiology with chemo-brain. T2D-related insulin resistance can precipitate repeated high blood sugar episodes which increase inflammatory molecule release. In individuals with T2D without cancer, negative relationships are observed between inflammatory molecule concentrations and the brain's vascular and/or cognitive function. Cancer survivors with T2D might thus have higher chemo-brain risk than those without T2D. Yet, more research must compare how the brain's vascular function, as well as cognitive, inflammatory, and cardiometabolic indices, differ between these groups. Physical activity (PA) counteracts chemo-brain's and T2D's pathophysiology, with higher PA/fitness resulting in better vascular function of the brain, lower inflammatory molecule concentrations, and improved insulin sensitivity. We are therefore conducting a 30-participant quasi-experimental pilot study in cancer survivors with (cases) and without (controls) T2D. We will first investigate between-group differences in the brain's vascular function as well as cognitive, inflammatory, cardiometabolic, and epigenetic outcomes. We will then examine between-group changes in these outcomes and select psychosocial metrics during a 12-week technology-based PA program-potentially further elucidating in
Primary Outcome
We will complete transcranial doppler assessments to measure middle cerebral artery velocity at rest and during exercise.
Conditions Studied
Interventions
- BEHAVIORAL Social Cognitive Theory-based, Technology-delivered Physical Activity Program
Study Locations (1)
Oklahoma
- University of Oklahoma Health Sciences - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT06725953 shows while recruiting
NCT06725953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 257-participant average among 11 other Cancer Survivorship trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Cancer Survivorship appearing as the primary indexed condition, and to 1 intervention - of which Social Cognitive Theory-based, Technology-delivered Physical Activity Program is the first listed.
NCT06725953 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06725953 about?
NCT06725953 is a clinical study titled "Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes". The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select pathophysiological processes. Research on chemotherapy-induced cognitiv...
What is the current status of trial NCT06725953?
This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2025-03-10. Estimated completion is 2026-05.
What conditions does trial NCT06725953 study?
This clinical trial studies the following conditions: Cancer Survivorship, Chemotherapy Side Effects.
What interventions are being tested in trial NCT06725953?
The interventions under investigation include: Social Cognitive Theory-based, Technology-delivered Physical Activity Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06725953?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06725953 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Survivorship
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06725953's enrollment target sits among peer trials
38 11th of 11 higher than 1 of 11 other Cancer Survivorship trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer Survivorship trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Cancer Survivors
RECRUITING · NA
-
Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors
RECRUITING · NA
-
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
RECRUITING · NA
-
mHealth Intervention for Pain Self Management
RECRUITING · NA
-
Family Building Decision Support for Female Adolescent and Young Adult Cancer Survivors
RECRUITING · NA
-
Cooperative Extension and Cancer Survivorship
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI